Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?
@article{HBSN104617, author = {Takeshi Hatanaka and Atsushi Naganuma and Yutaka Yata and Satoru Kakizaki}, title = {Atezolizumab plus bevacizumab and tremelimumab plus durvalumab: how should we choose these two immunotherapy regimens for advanced hepatocellular carcinoma?}, journal = {Hepatobiliary Surgery and Nutrition}, volume = {11}, number = {6}, year = {2022}, keywords = {}, abstract = {}, issn = {2304-389X}, url = {https://hbsn.amegroups.org/article/view/104617} }